Quotazioni in diretta

MRK Merck and Co Inc

127,22

-0,29 (-0,23%)

Ultimo aggiornamento: 19:05:21

Dati in Delay di 15 minuti

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Grafico Azioni Merck (NYSE:MRK)
Storico
Da Apr 2024 a Mag 2024

Clicca qui per i Grafici di Merck

Grafico Azioni Merck (NYSE:MRK)
Storico
Da Mag 2023 a Mag 2024

Clicca qui per i Grafici di Merck

Notizie Merck and Co Inc - MRK

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Mercoledì 1 Maggio 2024 (5 giorni fa) • Business Wire

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Lunedì 29 Aprile 2024 (1 settimana fa) • Business Wire

U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Giovedì 25 Aprile 2024 (2 settimane fa) • IH Market News

Futures Pointing To Sharply Lower Open On Wall Street
Giovedì 25 Aprile 2024 (2 settimane fa) • IH Market News

Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Giovedì 25 Aprile 2024 (2 settimane fa) • IH Market News

Merck Announces First-Quarter 2024 Financial Results
Giovedì 25 Aprile 2024 (2 settimane fa) • Business Wire

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta
Venerdì 19 Aprile 2024 (2 settimane fa) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Mercoledì 10 Aprile 2024 (4 settimane fa) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Giovedì 4 Aprile 2024 (1 mese fa) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Mercoledì 3 Aprile 2024 (1 mese fa) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Lunedì 1 Aprile 2024 (1 mese fa) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Giovedì 28 Marzo 2024 (1 mese fa) • Business Wire

Più Merck and Co Inc Articoli Notizie

Intesa Sanpaolo

Banca Monte Dei Paschi D...

ST Microelectronics

Terna Trasmissione Elett...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea